- Active not recruitingPHASE1, PHASE2
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This study looks at a new treatment called AUTO1 for adults with a type of blood cancer called B-cell acute lymphoblastic leukaemia (ALL) that has come back or not responded to previous treatments. It aims to see if AUTO1 is safe and effective.
For: Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaUnited States · Spain · United Kingdom - RecruitingPHASE1
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This study looks at a new type of cell therapy called CAR T-cell therapy (AUTO1) for children and teenagers with types of blood cancer (leukaemia or lymphoma) that haven't responded to other treatments. It checks how safe and effective it is.
For: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia · Relapsed or Refractory B Cell Non-Hodgkin LymphomaUnited States · Spain · United Kingdom - AuthorisedTherapeutic exploratory (Phase II)
A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS
This study is looking at a new treatment called obe-cel for severe lupus that affects the kidneys. We want to see if it helps reduce kidney problems and improve overall health, and if it's safe for people aged 18 and over.
For: Systemic Lupus Erythematosus with Active Lupus NephritisGreece